mProX™ Human NT5E Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD73, encoded by the NT5E gene, is involved in various cellular processes and has been implicated in tumor development. In nasopharyngeal carcinoma (NPC), CD73 expression is higher in tumor tissues compared to normal tissues, and its expression is associated with clinical stages, lymph node metastasis, and prognosis of NPC patients. Knocking down CD73 in NPC cells inhibits their malignant phenotype. In a study on aortic inflammation, CD73 deficiency did not aggravate immune cell recruitment or affect morphological or functional characteristics. In pancreatic cancer, CD73 is part of an immunogenic cell death-related prognostic signature and is associated with poor overall survival. In HER2-positive breast cancer, CD73 is a marker of reversible senescence and can be targeted for ultrasound molecular imaging to evaluate lapatinib resistance. In non-small cell lung cancer (NSCLC), proteasome inhibitors reduce CD73 expression by decreasing p-ERK levels, a component of the MAPK pathway. CD73 overexpression in NSCLC cells reduces the anticancer activity of proteasome inhibitors in vivo. These findings suggest that CD73 plays important roles in tumor behavior and may serve as a diagnostic marker and therapeutic target in various cancers.